The DOI matches its Crossref record; 340 of the 340 references it cites were found in a registry or an index.
Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)
Open accessAbstract
Background: The Infectious Diseases Society of America (IDSA) is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. The initial guidance document on infections caused by extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa) was published on 17 September 2020. Over the past year, there have been a number of important publications furthering our understanding of the management of ESBL-E, CRE, and DTR-P. aeruginosa infections, prompting a rereview of the literature and this updated guidance document. Methods: A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections reviewed, updated, and expanded previously developed questions and recommendations about the treatment of ESBL-E, CRE, and DTR-P. aeruginosa infections. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. Results: Preferred and alternative treatment recommendations are provided with accompanying rationales, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, duration of therapy, and other management considerations are also discussed briefly. Recommendations apply for both adult and pediatric populations. Conclusions: The field of antimicrobial resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial-resistant infections. This document is current as of 24 October 2021. The most current versions of IDSA documents, including dates of publication, are available at www.idsociety.org/practice-guideline/amr-guidance/.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–340 of 340
Mechanisms of β -lactam Resistance Among Pseudomonas aeruginosa
Wolter, D. J., & Lister, P. (2012) · Current Pharmaceutical Design · doi:10.2174/138161213804070311 · Cited by 73
Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance
Tamma, P. D., Beisken, S., Bergman, Y., Posch, A. E., Avdic, E., Sharara, S. L., Cosgrove, S. E., & Simner, P. J. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1306 · Cited by 72
Self-citationPfaller, M. A., Huband, M. D., Shortridge, D., & Flamm, R. K. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02327-17 · Cited by 71
Cefpodoxime vs Ciprofloxacin for Short-Course Treatment of Acute Uncomplicated Cystitis
Hooton, T. M., Roberts, P. L., & Stapleton, A. E. (2012) · JAMA · doi:10.1001/jama.2012.80 · Cited by 70
Wang, R., Cosgrove, S. E., Tschudin‐Sutter, S., Han, J., Turnbull, A. E., Hsu, A. J., Avdic, E., Carroll, K. C., & Tamma, P. D. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw132 · Cited by 70
Self-citationAitken, S. L., Tarrand, J. J., Deshpande, L. M., Tverdek, F. P., Jones, A. L., Shelburne, S. A., Prince, R. A., Bhatti, M. M., Rolston, K. V. I., Jones, R. N., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw398 · Cited by 68
Self-citationKarlowsky, J. A., Kazmierczak, K. M., Bouchillon, S. K., DeJonge, B. L. M., Stone, G. G., & Sahm, D. F. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02569-17 · Cited by 68
Rubio, A. M., Kline, E. G., Jones, C. E., Chen, L., Kreiswirth, B. N., Nguyen, M. H., Clancy, C. J., Cooper, V. S., Haidar, G., Tyne, D. V., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00084-21 · Cited by 66
Self-citationSader, H. S., Castanheira, M., & Flamm, R. K. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02083-16 · Cited by 65
Castanheira, M., Doyle, T. B., Kantro, V., Mendes, R. E., & Shortridge, D. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01951-19 · Cited by 65
Hobson, C. A., Bonacorsi, S., Fahd, M., Baruchel, A., Cointe, A., Poey, N., Jacquier, H., Doit, C., Monjault, A., Tenaillon, O., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02463-18 · Cited by 64
Naesens, R., Vlieghe, E., Verbrugghe, W., Jorens, P. G., & Ieven, M. M. (2011) · BMC Infectious Diseases · doi:10.1186/1471-2334-11-317 · Cited by 63
Pfaller, M. A., Huband, M. D., Shortridge, D., & Flamm, R. K. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02488-19 · Cited by 63
Defining Baseline Mechanisms of Cefiderocol Resistance in the Enterobacterales
Simner, P. J., Beisken, S., Bergman, Y., Ante, M., Posch, A. E., & Tamma, P. D. (2021) · Microbial Drug Resistance · doi:10.1089/mdr.2021.0095 · Cited by 63
Self-citationClinical Significance of the Pharmacokinetic and Pharmacodynamic Characteristics of Tigecycline
Falagas, M. E., Karageorgopoulos, D. E., & Dimοpoulos, G. (2009) · Current Drug Metabolism · doi:10.2174/138920009787048356 · Cited by 62
Sader, H. S., Flamm, R. K., Carvalhaes, C. G., & Castanheira, M. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01587-18 · Cited by 62
Castanheira, M., Duncan, L. R., Mendes, R. E., Sader, H. S., & Shortridge, D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02125-17 · Cited by 61
Alosaimy, S., Lagnf, A. M., Morrisette, T., Scipione, M. R., Zhao, J. J., Jorgensen, S. C. J., Mynatt, R. P., Carlson, T. J., Jo, J., Garey, K. W., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab371 · Cited by 61
Räisänen, K., Koivula, I., Ilmavirta, H., Puranen, S., Kallonen, T., Lyytikäinen, O., & Jalava, J. (2019) · Eurosurveillance · doi:10.2807/1560-7917.es.2019.24.19.1900256 · Cited by 60
Tamma, P. D., Sharara, S. L., Pana, Z. D., Amoah, J., Fisher, S. L., Tekle, T., Doi, Y., & Simner, P. J. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz353 · Cited by 60
Self-citationLob, S. H., Karlowsky, J. A., Young, K., Motyl, M. R., Hawser, S., Kothari, N., & Sahm, D. F. (2020) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001142 · Cited by 60
Fosfomycin for Treatment of Prostatitis: New Tricks for Old Dogs: Figure 1.
Grayson, M. L., Maćešić, N., Trevillyan, J. M., Ellis, A. G., Zeglinski, P. T., Hewitt, N. H., Gardiner, B. J., & Frauman, A. G. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ436 · Cited by 59
Shropshire, W. C., Aitken, S. L., Pifer, R., Kim, J., Bhatti, M. M., Li, X., Kalia, A., Galloway-Peña, J., Sahasrabhojane, P. V., Arias, C. A., et al. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa447 · Cited by 59
Self-citationKuo, S., Lee, Y.-T., Yang, S.-P., Chen, C.-P., Chen, T.-L., Hsieh, S.-L., Siu, L.-K. K., & Fung, C. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03682.x · Cited by 58
Pogue, J. M., Neelakanta, A., Mynatt, R. P., Sharma, S., Lephart, P., & Kaye, K. S. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu594 · Cited by 57
Karlowsky, J. A., Lob, S. H., Young, K., Motyl, M. R., & Sahm, D. F. (2018) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2018.07.012 · Cited by 57
Activity of Cefiderocol and Comparators against Isolates from Cancer Patients
Rolston, K. V. I., Gerges, B., Shelburne, S. A., Aitken, S. L., RAAD, I. I., & Prince, R. A. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01955-19 · Cited by 57
Self-citationInhaled colistin as monotherapy for multidrug-resistant gram (−) nosocomial pneumonia: A case series
Falagas, M. E., Siempos, I. Ι., Rafailidis, P. I., Korbila, I. P., Ioannidou, E., & Michalopoulos, A. S. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2008.11.018 · Cited by 56
Lin, C.-C., Liu, T.-C., Kuo, C.-F., Liu, C.-P., & Lee, C.-M. (2010) · Journal of Microbiology Immunology and Infection · doi:10.1016/s1684-1182(10)60050-3 · Cited by 56
Harris, P. N. A., Mo, Y., Jureen, R., Chew, J., Ali, J., Paynter, S., Paterson, D. L., & Tambyah, P. A. (2015) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-015-0055-6 · Cited by 56
Early Experience With Eravacycline for Complicated Infections
Alosaimy, S., Molina, K. C., Claeys, K. C., Andrade, J., Truong, J. Q., King, M. A., Pullinger, B. M., Huang, G., Morrisette, T., Lagnf, A. M., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa071 · Cited by 56
Sabour, S., Huang, J. Y., Bhatnagar, A. S., Gilbert, S. E., Karlsson, M., Lonsway, D., Lutgring, J. D., Rasheed, J. K., Halpin, A. L., Stanton, R. A., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01105-21 · Cited by 56
Sorlí, L., Luque, S., Li, J., Campillo, N., Danés-Castells, M., Montero, M., Segura, C., Grau, S., & Horcajada, J. P. (2019) · Journal of Infection · doi:10.1016/j.jinf.2019.06.011 · Cited by 55
Alosaimy, S., Jorgensen, S. C. J., Lagnf, A. M., Melvin, S. M., Mynatt, R. P., Carlson, T. J., Garey, K. W., Allen, D., Venugopalan, V., Veve, M. P., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa051 · Cited by 54
Shortridge, D., Pfaller, M. A., Castanheira, M., & Flamm, R. K. (2017) · Microbial Drug Resistance · doi:10.1089/mdr.2017.0266 · Cited by 53
Chen, Z., & Shi, X. (2018) · Medicine · doi:10.1097/md.0000000000012467 · Cited by 53
Cano, Á., Guzmán-Puche, J., García‐Gutiérrez, M., Castón, J. J., Gracia-Ahufinger, I., Pérez‐Nadales, E., Recio, M., Natera, A. M., Marfil, E., Martı́nez-Martı́nez, L., et al. (2019) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2019.11.007 · Cited by 53
Zhou, M., Wang, Y., Liu, C., Kudinha, T., Liu, X., Luo, Y., Yang, Q., Sun, H., Hu, J., & Xu, Y. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s166790 · Cited by 52
Oral fosfomycin for the treatment of chronic bacterial prostatitis
Karaiskos, I., Galani, L., Sakka, V., Gkoufa, A., Sopilidis, O., Chalikopoulos, D., Alivizatos, G. J., & Giamarellou, E. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz015 · Cited by 52
Karlowsky, J. A., Lob, S. H., Kazmierczak, K. M., Young, K., Motyl, M. R., & Sahm, D. F. (2019) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2019.10.028 · Cited by 52
Tamma, P. D., Smith, T. T., Adebayo, A., Karaba, S. M., Jacobs, E. B., Wakefield, T., Nguyen, T. H. D., Whitfield, N. N., & Simner, P. J. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00127-21 · Cited by 52
Self-citationSader, H. S., Flamm, R. K., Dale, G. E., Rhomberg, P. R., & Castanheira, M. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky227 · Cited by 51
Zamudio, R., Hijazi, K., Joshi, C., Aitken, E., Oggioni, M. R., & Gould, I. M. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.02.022 · Cited by 51
Lob, S. H., Hackel, M., Kazmierczak, K. M., Hoban, D. J., Young, K., Motyl, M. R., Karlowsky, J. A., & Sahm, D. F. (2017) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.02.018 · Cited by 50
Pfaller, M. A., Shortridge, D., Sader, H. S., Gales, A. C., Castanheira, M., & Flamm, R. K. (2017) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2017.06.008 · Cited by 50
Sader, H. S., Flamm, R. K., Carvalhaes, C. G., & Castanheira, M. (2019) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2019.05.005 · Cited by 50
Canver, M. C., Satlin, M. J., Westblade, L. F., Kreiswirth, B. N., Chen, L., Robertson, A., Fauntleroy, K. A., Spina, M. L., Callan, K., & Jenkins, S. G. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00672-19 · Cited by 50
Benchetrit, L., Mathy, V., Armand-Lefèvre, L., Bouadma, L., & Timsit, J. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.10.023 · Cited by 50
Elliott, Z. S., Barry, K. E., Cox, H. L., Stoesser, N. E., Carroll, J., Vegesana, K. B., Kotay, S. M., Sheppard, A. E., Wailan, A. M., Crook, D. W., et al. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.00634-19 · Cited by 49
Self-citationGolden, A., Adam, H. J., Baxter, M. R., Walkty, A. J., Lagacé-Wiens, P. R. S., Karlowsky, J. A., & Zhanel, G. G. (2020) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2020.115012 · Cited by 49
Tsai, H.-Y., Chen, Y., Tang, H.-J., Huang, C.-C., Liao, C., Chu, F., Chuang, Y.-C., Sheng, W., Ko, W., & Hsueh, P. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.07.006 · Cited by 48
Yoon, Y. K., Kim, J. H., Sohn, J. W., Yang, K., & Kim, M. J. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.12.017 · Cited by 47
Carvalhaes, C. G., Castanheira, M., Sader, H. S., Flamm, R. K., & Shortridge, D. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.11.021 · Cited by 47
Collaborators, O. B. O. T. S., Galani, I., Souli, M., Nafplioti, K., Adamou, P., Karaiskos, I., Giamarellou, H., & Antoniadou, A. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03517-y · Cited by 47
Jang, J. Y., Kwon, H. Y., Choi, E. H., Lee, W., Shim, H., & Bae, K. S. (2017) · Journal of Critical Care · doi:10.1016/j.jcrc.2017.04.004 · Cited by 46
Balabanian, G., Rose, M., Manning, N., Landman, D., & Quale, J. M. (2018) · Microbial Drug Resistance · doi:10.1089/mdr.2018.0065 · Cited by 46
Karlowsky, J. A., Lob, S. H., Kazmierczak, K. M., Young, K., Motyl, M. R., & Sahm, D. F. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00169-18 · Cited by 46
Characterization of carbapenem-resistant but cephalosporin-susceptible Pseudomonas aeruginosa
Khalili, Y., Yekani, M., Goli, H. R., & Memar, M. Y. (2019) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.66.2019.036 · Cited by 46
Kuo, S., Wang, Y.-C., Tan, M.-C., Huang, W., Shiau, Y., Wang, H., Lai, J., Huang, I., & Lauderdale, T.-L. Y. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab141 · Cited by 46
Mechanisms of carbapenem resistance in cephalosporin-susceptible Pseudomonas aeruginosa in China
Zeng, Z., Wang, W., Huang, M., Shi, L.-N., Wang, Y., & Shao, H. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.11.014 · Cited by 44
Campana, E. H., Xavier, D. E., Petrolini, F. V. B., Cordeiro-Moura, J. R., de Araújo, M. R. E., & Gales, A. C. (2016) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2016.10.008 · Cited by 44
Pfaller, M. A., Shortridge, D., Sader, H. S., Castanheira, M., & Flamm, R. K. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.09.016 · Cited by 44
Johnston, B., THURAS, P. D., Porter, S. B., Anacker, M. L., VonBank, B., Vagnone, P. S., Witwer, M. L., Castanheira, M., & Johnson, J. R. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00797-20 · Cited by 44
Yang, C., Li, S.-H., Chuang, F., Chen, C., Lee, C.-H., Chen, J., Wu, C., & Lee, C. (2012) · BMC Infectious Diseases · doi:10.1186/1471-2334-12-206 · Cited by 43
Pseudomonas aeruginosa Susceptible Only to Colistin in Intensive Care Unit Patients
Mastoraki, A. T., Douka, E., Kriaras, I., Stravopodis, G., Manoli, H., & Geroulanos, S. (2008) · Surgical Infections · doi:10.1089/sur.2007.004 · Cited by 43
Lob, S. H., Hoban, D. J., Young, K., Motyl, M. R., & Sahm, D. F. (2018) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2018.05.017 · Cited by 43
Kim, Y. K., Lee, J. H., Lee, H.-K., Chung, B. C., Yu, S. J., Lee, H., Park, J. H., Kim, S., Kim, H.-K., Kiem, S., et al. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.02.61 · Cited by 42
Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015–17
Lob, S. H., Karlowsky, J. A., Young, K., Motyl, M. R., Hawser, S., Kothari, N., Gueny, M. E., & Sahm, D. F. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz191 · Cited by 42
Lee, C., Su, L., Chen, F., Tang, Y.-F., Li, C.-C., Chien, C., & Liu, J.-W. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.07.020 · Cited by 41
Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae
Pilmis, B., Parize, P., Zahar, J., & Lortholary, O. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-014-2094-y · Cited by 41
Zhao, C., Wang, X., Zhang, Y., Wang, R., Wang, Q., Li, H., & Wang, H. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4093-1 · Cited by 41
Shortridge, D., Pfaller, M. A., Castanheira, M., & Flamm, R. K. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.05.011 · Cited by 40
Khil, P. P., Chiang, A. D., Ho, J., Youn, J.-H., Lemon, J. K., Gea‐Banacloche, J., Frank, K. M., Parta, M., Bonomo, R. A., & Dekker, J. P. (2019) · mBio · doi:10.1128/mbio.01822-19 · Cited by 40
Self-citationKang, C.-H., Tsai, C., Wu, T.-H., Wu, H.-Y., Chung, M., Chen, C., Huang, Y., Liu, S., Liao, D., Niu, C.-K., et al. (2013) · Pediatric Pulmonology · doi:10.1002/ppul.22750 · Cited by 38
Lob, S. H., DePestel, D. D., DeRyke, C. A., Kazmierczak, K. M., Young, K., Motyl, M. R., & Sahm, D. F. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab320 · Cited by 38
Inhaled Colistin for Treatment of Pneumonia due to Colistin-Only-SusceptibleAcinetobacter baumannii
Choi, H. K., Kim, Y. K., Kim, H. Y., & Uh, Y. (2013) · Yonsei Medical Journal · doi:10.3349/ymj.2014.55.1.118 · Cited by 36
Yang, T.-Y., Hsieh, Y., Kao, L.-T., Liu, G. H., Lian, S.-H., Wang, L., Lin, I., Wang, H.-Y., Tseng, S., & Lu, P. (2021) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2021.02.001 · Cited by 36
Ko, J., Lee, N. R., Joo, E., Moon, S., Choi, J. ‐., Park, D. A., & Peck, K. R. (2017) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-017-3133-2 · Cited by 35
Li, S., Jia, X., Li, C., Zou, H., Liu, H., Guo, Y., & Zhang, L. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s174876 · Cited by 35
Karlowsky, J. A., Lob, S. H., Kazmierczak, K. M., Young, K., Motyl, M. R., & Sahm, D. F. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.10.022 · Cited by 35
Gajdács, M. (2020) · Antibiotics · doi:10.3390/antibiotics9040153 · Cited by 35
Hsieh, T.-C., Chen, F.-L., Ou, T.-Y., Jean, S., & Lee, W. (2014) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2014.08.009 · Cited by 34
Sader, H. S., Castanheira, M., Farrell, D. J., Flamm, R. K., & Jones, R. N. (2015) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2015.06.008 · Cited by 34
Huband, M. D., Castanheira, M., Flamm, R. K., Farrell, D. J., Jones, R. N., & Sader, H. S. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03056-15 · Cited by 34
Boulant, T., Jousset, A. B., Bonnin, R. A., Barrail‐Tran, A., Borgel, A., Oueslati, S., Naas, T., & Dortet, L. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01637-19 · Cited by 34
Beytur, A., Yakupoğulları, Y., Oğuz, F., et al. (2014) · Jundishapur Journal of Microbiology · doi:10.5812/jjm.13792 · Cited by 33
Use of colistin in treating multi-resistant Gram-negative organisms in a specialised burns unit
Ganapathy, H., Pal, S. K., Teare, L., & Dziewulski, P. G. (2009) · Burns · doi:10.1016/j.burns.2009.07.010 · Cited by 32
Ren, H., Li, X., Ni, Z., Niu, J., Cao, B., Xu, J., Cheng, H., Tu, X., Ren, A.-M., Hu, Y., et al. (2017) · International Urology and Nephrology · doi:10.1007/s11255-017-1507-0 · Cited by 32
Castanheira, M., Arends, S. J. R., Davis, A. P., Woosley, L. N., Bhalodi, A. A., & MacVane, S. H. (2018) · mSphere · doi:10.1128/msphere.00408-18 · Cited by 32
Castanheira, M., Doyle, T. B., Hubler, C. M., Sader, H. S., & Mendes, R. E. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106011 · Cited by 31
Sader, H. S., Castanheira, M., Flamm, R. K., & Jones, R. N. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00405-16 · Cited by 30
Sutherland, C. A., Verastegui, J. E., & Nicolau, D. P. (2016) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-016-0155-z · Cited by 30
Atkin, S. D., Abid, S., Foster, M., Bose, M., Keller, A. E., Hollaway, R., Sader, H. S., Greenberg, D. E., Finklea, J. D., Castanheira, M., et al. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s173804 · Cited by 30
So, W., Shurko, J. F., Galega, R., Quilitz, R. E., Greene, J. N., & Lee, G. C. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky393 · Cited by 30
Sieswerda, E., van den Brand, M., van den Berg, R. B., Sträter, J., Schouls, L. M., van Dijk, K., & Budding, A. E. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz495 · Cited by 30
Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia
Paterson, D. L., Henderson, A., & Harris, P. N. A. (2019) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000623 · Cited by 30
696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies
Ito, A., Nishikawa, T., Ishii, R., Kuroiwa, M., Ishioka, Y., Kurihara, N., Sakikawa, I., Ota, T., Rokushima, M., Tsuji, M., et al. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy210.703 · Cited by 29
Sader, H. S., Carvalhaes, C. G., Streit, J. M., Doyle, T. B., & Castanheira, M. (2020) · Microbial Drug Resistance · doi:10.1089/mdr.2020.0217 · Cited by 29
Bitterman, R., Koppel, F., Mussini, C., Geffen, Y., Chowers, M., Rahav, G., Nesher, L., Ben‐Ami, R., Turjeman, ., Samuel, M. H., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-040210 · Cited by 29
Venditti, C. C., Nisii, C., D’Arezzo, S., Vulcano, A., Capone, A., Antonini, M., Ippolito, G., & Di, A. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s207993 · Cited by 28
Tamma, P. D., & Humphries, R. M. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlab019 · Cited by 28
Self-citationSader, H. S., Duncan, L. R., Doyle, T. B., & Castanheira, M. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlab126 · Cited by 28
Musher, D. M., Minuth, J. N., Thorsteinsson, S. B., & Holmes, T. (1975) · The Journal of Infectious Diseases · doi:10.1093/infdis/131.supplement.s40 · Cited by 27
Kim, S. A., Altshuler, J., Paris, D., & Fedorenko, M. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.09.013 · Cited by 27
Xiao, T., Yang, K., Zhou, Y., Zhang, S., Ji, J., Ying, C., Shen, P., & Xiao, Y. (2019) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-019-0599-y · Cited by 27
Sénard, O., Lafaurie, M., Lesprit, P., Nguyen, Y., Lescure, F.-X., Therby, A., Fihman, V., Oubaya, N., & Lepeule, R. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03701-0 · Cited by 26
Castanheira, M., Sader, H. S., Mendes, R. E., & Jones, R. N. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02418-19 · Cited by 26
Zhou, M., Yang, Q., Lomovskaya, O., Sun, D., Kudinha, T., Xu, Z., Zhang, G., Chen, X., & Xu, Y. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky251 · Cited by 25
Wang, C.-C., Chao, T.-Y., Chen, Y., Fang, W., Kao, H., Chen, H., Tsai, Y.-C., Shen, L.-S., Li, C.-L., Chang, H., et al. (2014) · Biomedical Journal · doi:10.4103/2319-4170.132879 · Cited by 24
Dizbay, M., Özger, H. S., Karaşahin, Ö., & Karaşahin, E. F. (2016) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1506-157 · Cited by 24
Biagi, M. J., Butler, D. A., Tan, X., Qasmieh, S., & Wenzler, E. (2019) · Antibiotics · doi:10.3390/antibiotics8010027 · Cited by 24
In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017–2018
Dong, D., Zheng, Y., Chen, Q., Guo, Y. P., Yang, Y., Wu, S., Zhu, D., Deng, D., Bradford, P. A., Reinhart, H. H., et al. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03877-w · Cited by 24
Pfaller, M. A., Shortridge, D., Sader, H. S., Flamm, R. K., & Castanheira, M. (2017) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2017.05.025 · Cited by 23
Karlowsky, J. A., Lob, S. H., Young, K., Motyl, M. R., & Sahm, D. F. (2019) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2019.05.001 · Cited by 23
Johnston, B., THURAS, P. D., Porter, S. B., Anacker, M. L., VonBank, B., Vagnone, P. S., Witwer, M. L., Castanheira, M., & Johnson, J. R. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02408-19 · Cited by 23
Smith, K. P., Brennan-Krohn, T., Weir, S. K., & Kirby, J. E. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.02128-16 · Cited by 21
Kulengowski, B., & Burgess, D. S. (2019) · Pathogens and Disease · doi:10.1093/femspd/ftz040 · Cited by 21
Karlowsky, J. A., Lob, S. H., Young, K., Motyl, M. R., & Sahm, D. F. (2020) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piaa056 · Cited by 21
Iregui, A., Landman, D., & Quale, J. M. (2020) · Microbial Drug Resistance · doi:10.1089/mdr.2019.0423 · Cited by 21
In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii
Noel, A., Attwood, M., Bowker, K. E., & MacGowan, A. P. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa508 · Cited by 21
CON: Testing for ESBL production is unnecessary for ceftriaxone-resistant Enterobacterales
Mathers, A. J., & Lewis, J. S. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlab020 · Cited by 21
Self-citationZhang, H., Jia, P., Zhu, Y., Zhang, G., Zhang, J., Kang, W., Duan, S., Zhang, W., Yang, Q., & Xu, Y. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s325520 · Cited by 21
Sader, H. S., Castanheira, M., Flamm, R. K., Huband, M. D., & Jones, R. N. (2016) · Surgical Infections · doi:10.1089/sur.2016.036 · Cited by 20
The Role of Aerolized Colistin in the Treatment of Hospital-Acquired Pneumonia
Ekren, P. K., Töreyin, Z. N., Sayıner, A., & Bacakoğlu, F. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001539 · Cited by 19
Nasir, N., Ahmed, S., Razi, S., Awan, S., & Mahmood, S. F. (2019) · BMC Research Notes · doi:10.1186/s13104-019-4648-7 · Cited by 19
Jean, S., Hsieh, T.-C., Lee, W., Hsueh, P., Hsu, C.-W., & Lam, C. (2018) · Medicine · doi:10.1097/md.0000000000012278 · Cited by 18
Lepeule, R., Leflon‐Guibout, V., Vanjak, D., Zahar, J., Lafaurie, M., Besson, C., & Lefort, A. (2014) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2014.09.004 · Cited by 16
Sears, C. L., File, T. M., Alexander, B. D., McQuillen, D. P., MacIntyre, A. T., Allen, U., Colasanti, J. A., Siddiqui, J., Reveles, K. R., Busky, C., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1040 · Cited by 16
Elbaz, M., & Ben‐Ami, R. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa369 · Cited by 15
Meini, S., Laureano, R., Tascini, C., Arena, F., Fani, L., Frullini, A., Passaleva, M. T., Roberts, A. T., Mannini, D., Sbrana, F., et al. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.10.014 · Cited by 13
Gill, C. M., Aktaş, E., Alfouzan, W. A., Bourassa, L. A., Brink, A. J., Burnham, C. D., Cantón, R., Carmeli, Y., Falcone, M., Kiffer, C. R. V., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01204-21 · Cited by 13
Zaidenstein, R., Miller, A., Tal-Jasper, R., Ofer-Friedman, H., Sklarz, M. Y., Katz, D. E., Lazarovitch, T., Lephart, P., Mengesha, B., Tzuman, O., et al. (2018) · Microorganisms · doi:10.3390/microorganisms6010009 · Cited by 12
Walkty, A. J., Karlowsky, J. A., Baxter, M. R., Adam, H. J., Golden, A., Lagacé-Wiens, P. R. S., & Zhanel, G. G. (2021) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2021.115418 · Cited by 11
Sader, H. S., Castanheira, M., Jones, R. N., & Flamm, R. K. (2016) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2016.11.019 · Cited by 10
Stewart, A. G., Cottrell, K., Henderson, A., Vemuri, K. R., Bauer, M. J., Paterson, D. L., & Harris, P. N. A. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00226-21 · Cited by 10
Mukerji, A. C., Sharma, M., Taneja, O. P., Saxena, S. N., Bhatnagar, R. K., & Ghosh-Ray, B. (2009) · Chemotherapy · doi:10.1159/000220613 · Cited by 8
Lob, S. H., Hackel, M., Young, K., Motyl, M. R., & Sahm, D. F. (2021) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2021.115421 · Cited by 7
Horwich-Scholefield, S., Lloyd, T., Varghese, V., Yette, E., Huang, S., & Pandori, M. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02288-20 · Cited by 7
Minocycline in the Treatment of Carbapenem-Resistant Klebsiella pneumoniae
Khatri, A. M., Lobo, S. A., Nog, R., Lee, L., Wang, G., & Dhand, A. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx163.221 · Cited by 5
Talan, D. A., Stamm, W. E., Hooton, T. M., Moran, G. J., Burke, T., Iravani, A., Reuning-Scherer, J., & Church, D. A. (2000) · JAMA · doi:10.1001/jama.283.12.1583
Cited by
Karampatakis, T., Tsergouli, K., & Behzadi, P. (2023) · Antibiotics · doi:10.3390/antibiotics12020234 · Cited by 339
Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics
Wood, S. J., Kuzel, T. M., & Shafikhani, S. H. (2023) · Cells · doi:10.3390/cells12010199 · Cited by 254
Klebsiella pneumoniae carbapenemase variants: the new threat to global public health
Ding, L., Shen, S., Chen, J., Tian, Z., Shi, Q., Han, R., Guo, Y., & Hu, F. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-23 · Cited by 222
Rajakani, S. G., Xavier, B. B., Sey, A., Mariem, E. B., Lammens, C., Goossens, H., Glupczynski, Y., & Malhotra-Kumar, S. (2023) · Genes · doi:10.3390/genes14071426 · Cited by 17
Metadata
- Authors
- Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-04-19
- Volume
- 75
- Issue
- 2
- Pages
- 187-212
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W4224266833
- Cited by
- 526
- References
- 340
- FWCI
- 29.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.